AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2023
Feb 3, 2023
30849_dirs_2023-02-03_6777628b-cdab-4fe0-8d09-223b9c6aeb4f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2023-02-01
Reporting Person: Cramer Pamela J. (Chief Human Resources Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-01 | Restricted Stock Units | $ | A | 10600 | Acquired | Common Stock (10600) | Direct | |
| 2023-02-01 | Stock Option (Right to Buy) | $27.35 | A | 26800 | Acquired | 2033-01-31 | Common Stock (26800) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.
F3: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.